Latest news with #EuronextGrowth
Euronews
01-08-2025
- Business
- Euronews
Euronext bids for the Greek stock exchange: Here's what it means
Greek Minister of National Economy and Finance, Kyriakos Pierrakakis, described the acquisition of the Athens Stock Exchange by the European stock market group Euronext as 'one of the largest foreign investments in recent years". "For the Greek economy as a whole, this is a decisive step forward," Pierrakakis said from the floor of the Parliament. The announcement of the all-share deal came on Thursday, with the offer worth €412.8 million. "This is one of the largest foreign investments in recent years," continued Pierrakakis. "It strengthens our credibility and upgrades the country's position on the European and international economic map. We will examine the details of the agreement and follow the progress of its implementation. Overall, this is a highly positive development, and undoubtedly a major opportunity for the country as a whole." What it means for Greek businesses The integration of the Greek stock exchange into Euronext's European family opens a new gateway to financing for Greek companies, at a critical time when international competition is increasing and global trade is being redefined. Euronext is the largest liquidity pool in Europe, managing around 25% of total cash equity trading activity. It operates capital markets in major financial centres such as Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris. It brings the following to Greece: Access to a wider investment base Membership of a pan-European group offers Greek businesses direct exposure to a much larger network of international investors, both institutional and private. This translates into increased liquidity for their shares and greater chances of success in future capital raises or bond issuances. Know-how and digital tools Euronext has well-developed digital platforms, trading tools and compliance infrastructure that will support the technological modernisation of the Greek stock exchange. This will help more firms and investors to participate in the ecosystem. Enhancing credibility and prestige Participation in a network with a strong European presence could act as a "seal of credibility" for listed Greek companies, making them more attractive to foreign investors. Easier access for SMEs Euronext's focus on small and medium-sized enterprises (SMEs), through initiatives such as the 'Euronext Growth' programme, could lead to the development of simpler and less expensive listing procedures for Greek SMEs. Interconnection with other capital ecosystems Through Euronext, Greek companies will gain access to alternative financing tools such as green bonds, ESG ratings, dividend reinvestment programmes. What it means for the Greek economy The acquisition of the Greek stock exchange comes at an important juncture for the Greek economy, which continues to record significant GDP growth (2.3% in 2024), yet faces serious challenges. The main challenges include the completion of the Resilience and Recovery Fund, the looming recession threatening the European economy, and the need to change the country's production model, with less reliance on services such as tourism. Greek businesses need sources of funding in order to develop beyond the Greek market, which is small and showing signs of fatigue in terms of domestic consumption. Furthermore, despite the impressive increase in foreign direct investment over the last five years, the country still suffers from a large investment gap, hindering the modernisation of the Greek economy.
Yahoo
31-07-2025
- Business
- Yahoo
Pet Service Holding Achieves 14% Revenue Growth in the First Half of 2025
ZAANSTAD, Netherlands, July 31, 2025--(BUSINESS WIRE)--Regulatory News: Pet Service Holding (Paris:ALPET), the only company listed on Euronext Growth in Europe that is fully dedicated to pet health and well-being, achieved a 14% revenue growth in the first half of 2025 compared to the same period in 2024, reaching c. €7 million in revenue. This solid growth highlights Pet Service Holding's strong position in a rapidly expanding European pet market. The number of households with pets continues to rise; currently, more than 80 million European households have a named pet. At the same time, spending on pet food, health, and innovative solutions is increasing. According to Bloomberg, this trend is expected to continue at least through 2030. "Our growth demonstrates that we are successfully responding to structural market developments," said Ron van Veldhoven, CEO of Pet Service Holding. "Thanks to our integrated approach, we offer a comprehensive range of high-quality products and services that optimally support pets and their owners." Pet Service Holding combines veterinary pharmacies, wholesalers, online shops, and digital platforms into one powerful ecosystem. The company provides solutions in the areas of nutrition, health, and smart technology for pets. Pet Service Holding is listed on Euronext Growth under the ticker ALPET. This listing, effective since 28 July 2025, reflects the company's efforts to enhance its visibility and corporate governance. Moreover, it provides the company with efficient access to capital for further growth and strategic acquisitions. About Pet Service Holding Pet Service Holding NV is a leader in the field of animal care in the Netherlands. We aim to distinguish ourselves in this competitive market by bringing together a range of services and capitalizing on its valuable experience and expertise in this field. With a focus on animal supplies and nutrition and supplies for veterinary practices, we are well positioned to meet the needs of animals and their owners in Europe. Ticker: ALPET (Euronext Growth Paris) - ISIN: NL0015001HZ9 Also listed on: NXchange Amsterdam (ISIN: NL00150004O8). View source version on Contacts Pet Service Holding Ron van VeldhovenChief Executive Officer +31-75-7572685info@ NewCap Dusan OresanskyInvestor Relations +33 1 44 71 94 92petserviceholding@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
31-07-2025
- Business
- Business Wire
Pet Service Holding Achieves 14% Revenue Growth in the First Half of 2025
ZAANSTAD, Netherlands--(BUSINESS WIRE)--Regulatory News: Pet Service Holding (Paris:ALPET), the only company listed on Euronext Growth in Europe that is fully dedicated to pet health and well-being, achieved a 14% revenue growth in the first half of 2025 compared to the same period in 2024, reaching c. €7 million in revenue. This solid growth highlights Pet Service Holding's strong position in a rapidly expanding European pet market. The number of households with pets continues to rise; currently, more than 80 million European households have a named pet. At the same time, spending on pet food, health, and innovative solutions is increasing. According to Bloomberg, this trend is expected to continue at least through 2030. 'Our growth demonstrates that we are successfully responding to structural market developments,' said Ron van Veldhoven, CEO of Pet Service Holding. 'Thanks to our integrated approach, we offer a comprehensive range of high-quality products and services that optimally support pets and their owners.' Pet Service Holding combines veterinary pharmacies, wholesalers, online shops, and digital platforms into one powerful ecosystem. The company provides solutions in the areas of nutrition, health, and smart technology for pets. Pet Service Holding is listed on Euronext Growth under the ticker ALPET. This listing, effective since 28 July 2025, reflects the company's efforts to enhance its visibility and corporate governance. Moreover, it provides the company with efficient access to capital for further growth and strategic acquisitions. About Pet Service Holding Pet Service Holding NV is a leader in the field of animal care in the Netherlands. We aim to distinguish ourselves in this competitive market by bringing together a range of services and capitalizing on its valuable experience and expertise in this field. With a focus on animal supplies and nutrition and supplies for veterinary practices, we are well positioned to meet the needs of animals and their owners in Europe. Ticker: ALPET (Euronext Growth Paris) - ISIN: NL0015001HZ9 Also listed on: NXchange Amsterdam (ISIN: NL00150004O8).
RTÉ News
30-07-2025
- Business
- RTÉ News
Datalex announces intention to delist from Euronext Growth index
Airline e-commerce platform Datalex said today it plans to seek shareholder approval for a transition to private ownership by delisting its shares from the Euronext Growth index. Datalex said that after conducting a review of the benefits and drawbacks to its listing on Euronext Growth, its board decided that a move to private ownership is in the best interests of the company and its shareholders. In reaching its conclusion Datalex said its long-term vision and requirements of the business differ from those in 2000 when the company first listed. Datalex also issued a trading update today for the six months to the end of June, which showed further revenue growth on its Stellex platform, a "step change" in gross profit and a return to positive foreign exchange adjusted EBITDA. Revenues for the six month period rose by 9% to $14.5m from $13.2m the same time last year, with revenues from its Stellex platform soaring by 188% to $4m from $1.4m. Datalex said its gross profit jumped by 68% to $6.4m from $3.8m, while its loss after tax narrowed to $2.3m from $3.7m the same time last year. The company said that trading for the full year remains in line with expectations, and it is confident in achieving its FY2025 targets. "With strong progress in H1 2025 and continued execution of our growth strategy, Datalex is well-positioned to deliver sustainable revenue growth and return to full-year EBITDA profitability," it added. Datalex also said today that it intends to raise $6m in additional capital, via a debt raise, to facilitate its next growth phase and to best position Datalex to maximise its long-term strategic objectives. Jonathan Rockett, Datalex's CEO, said the compay achieved a "strong" financial performance in the first half of 2025, with trading for the full year continuing in line with expectations. "We have delivered several important milestones in the first half of 2025, most significantly the continued expansion of Stellex capabilities into our airline customers and also the launch of our latest product, DLX Pay. We are pleased to have signed Air Transat as the inaugural DLX Pay customer, with a go-live planned for later this year," he said. "In parallel, we are announcing a €6m debt facility to support our medium-term strategic priorities and our investment in product innovation. We expect this capital raise to close in August 2025," he added. He also said that delisting from Euronext Growth will better position the company to focus on strategic execution, accelerate innovation, and unlock greater long-term value for its customers and shareholders. "The move aligns with our aim to be a true catalyst for value-creating change for our airline partners and enhance Datalex's position at the top table of airline technology vendors globally," Mr Rockett said. "Our focus remains clear - create value for our airlines, grow Stellex platform revenues and return to sustained EBITDA profitability. I am pleased to report that while we have a lot to do to achieve our ambitions, we are on track and our efforts are now starting to translate to materially improved financial performance," he added.
Business Wire
28-07-2025
- Business
- Business Wire
Mauna Kea Technologies Reports First Half 2025 Revenue
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced its revenue for the first half and the first two quarters of 2025, ended June 30, 2025. First Half of 2025 Performance Summary Total revenue for the first half of 2025 amounted to €3.7m, representing a slight decline of 5% compared to H1 2024. U.S. revenue for the first half of 2025 grew by +14% as reported and +17% in constant currency, with a significant dollar depreciation against the euro, especially in Q2 2025. U.S. operations remained robust, with accelerated growth in Q2 2025: sales rose +23% at constant currency vs. Q2 2024, and up +11% in Q1 2025 vs. Q1 2024, boosted by the expansion of the sales team. Growth in the U.S. was primarily driven by system and probe sales, particularly in the pancreatic cysts indication, more than offsetting a decline in PPU revenue due to the gradual impact of lower Medicare reimbursement rates starting in 2024. In Europe, business activity was gradually impacted by the Company's financial context. However, this decline was almost entirely offset by strong performances in other regions. Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, stated: 'This first half confirms the relevance of our strategic decisions in our primary market, the United States, where we are seeing continued and sustained sales growth. This momentum is all the more noteworthy given that it was achieved with a reduced sales force, reflecting a strong increase in sales productivity per representative, now at a record level of over $900K, compared to just $200K in 2021. W e are also observing increased usage of Cellvizio and growing interest from new centers, particularly for indications such as pancreatic cysts and food intolerances. Pay-per-use procedure volumes have remained stable at over 800 per quarter for the past year, despite the reduction in Medicare reimbursement. The signing of three new hospitals at the end of H1 gives us confidence in a rebound in volumes going forward. I n Europe and the rest of the world, where our approach remains more opportunistic due to the lack of reimbursement, our activity was impacted by the financial environment. We are currently restructuring the organization to quickly improve efficiency in the coming months, including geographic expansion into high-potential markets such as Australia, which we recently announced. T he financial situation currently faced by Mauna Kea has, of course, had an impact on the Company's operations. However, the slight decline in revenue for the first half reflects the resilience of our business model. During this period of focus on restructuring efforts, we view the revenue level achieved in H1 as a solid performance.' Update on Safeguard Procedure On July 10, 2025, Mauna Kea Technologies received court approval to initiate a "classes of affected parties" procedure, a framework introduced by the 2021 reform of France's business insolvency law. This process groups creditors into different classes to vote on a comprehensive restructuring plan. In this framework, Mauna Kea Technologies will present a plan in the coming weeks, aimed at significantly reducing its debt, to be submitted to the vote by the various creditor classes. As a reminder, the Company's current cash runway extends through November 2025. Discussions are underway, as part of this safeguard procedure, with strategic investors and family offices to secure long-term financing to support its sustainable development plan toward profitability. Key Highlights for the First Half 2025 U.S. Commercial Productivity U.S. Commercial Productivity 2021 2022 2023 2024 Q1 2025 Q2 2025 Revenue per sales rep (in $K) 1 281 551 629 626 832 913 Avg. number of sales reps (over the period) 17 8 8 6 4 6 Expand As of January 1 st, 2025, the U.S. sales team had 4 representatives, down from 8 at the beginning of 2024. Despite this reduction, the revenue increased significantly over the half year period. Since mid-2024, new initiatives have been implemented, both in terms of sales tactics in response to Medicare reimbursement cuts and sales organization effectiveness, with the promotion of two representatives to national leadership roles. These actions have led to a significant increase in per-rep productivity, reaching historic levels of around $800K to $900K in annual sales per representative. This positive momentum also supported the hiring of two new sales representatives during the first half of 2025, who quickly became operational. Pay-Per-Use (PPU) Procedure Volumes PPU procedure volume, which had gradually slowed in 2024 due to Medicare reimbursement cuts, has stabilized at over 800 procedures per quarter. At the end of Q2 2025, three new PPU accounts were signed, marking the first new contracts since Q3 2024. This recovery signals renewed commercial momentum and indicates potential for volume rebound. Furthermore, the Company is actively working toward a reimbursement reclassification, notably by correcting hospital-submitted reporting data and collaborating closely with physician associations and Medicare authorities. Revenue by Geography – H1 2025 By geography, business was mainly driven by the U.S., where the Company recorded a +14% growth as reported and +17% at constant currency (CC), with a dollar depreciation against the euro, especially in Q2 2025. This growth was primarily driven by system and probe sales, particularly in the pancreatic cysts indication, offsetting a decline in PPU revenue due to the gradual impact of lower Medicare reimbursement rates starting in 2024. In Europe, business activity was gradually impacted by the Company's financial context. However, this decline was almost entirely offset by strong performances in other regions. Revenue by Category – H1 2025 'We remain fully committed to ensuring that the safeguard procedure results in a situation that allows Mauna Kea Technologies to achieve financial stability. At the same time, we are actively structuring the financial resources necessary to execute our development plan, with the aim of transforming Mauna Kea into a Company that delivers both growth and profitability", concluded Sacha Loiseau. A ppendix - Details of Revenue for Q1 and Q2 2025 About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website ( as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document. 1 Annualized sales for the first and second quarters of 2025
